Inflammatory Bowel Disease (IBD) Therapeutics

World Market Report

MCP-6282

EXECUTIVE ENGAGEMENTS

POOL

8361
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1171
Interactions with Platform & by Email

PARTICIPANTS

251
Unique # Participated

VALIDATIONS

87
Responses Validated*

COMPANIES

69
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2022

TABLES

61

PAGES

146

EDITION

18

PRICE

USD 5450

CODE

MCP-6282


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

STRONG ACTIVE NICHE TRIVIAL

%

VALIDATED RESEARCH *

S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T
S A N T

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What's New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Amid the COVID-19 crisis, the global market for Inflammatory Bowel Disease (IBD) Therapeutics estimated at US$20.6 Billion in the year 2020, is projected to reach a revised size of US$27.9 Billion by 2027, growing at a CAGR of 4.5% over the analysis period 2020-2027. TNF inhibitors, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$11.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anti-integrin segment is readjusted to a revised 4.3% CAGR for the next 7-year period.
The Inflammatory Bowel Disease (IBD) Therapeutics market in the U.S. is estimated at US$5.6 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.9 Billion by the year 2027 trailing a CAGR of 7.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.2% and 3.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.
In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 3.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.7 Billion by the year 2027, while Latin America will expand at a 4.3% CAGR through the analysis period.

SELECT PLAYERS

4SC AG; Abbott Nutrition; AbbVie, Inc.; Ablynx NV; Active Biotech AB; Alfasigma S.p.A.; Allergan PLC; Allergan PLC; Amgen, Inc.; Astellas Pharma, Inc.; AstraZeneca PLC; Athersys, Inc.; Atlantic Healthcare plc; Avaxia Biologics, Inc.; Biosafe Systems, LLC; Boehringer Ingelheim GmbH; Cadila Healthcare Ltd.; Celgene Corporation; Celltrion, Inc.; Cipla Ltd.; Coherus Biosciences, Inc.; Cosmo Pharmaceuticals NV; Dr. Falk Pharma GmbH; EA Pharma Co., Ltd.; Eddingpharm; EPIRUS Biopharmaceuticals, Inc.; F. Hoffmann-La Roche AG; F. Hoffmann-La Roche AG; Galapagos NV; Giaconda Ltd.; Google LLC; Immunic, Inc.; InDex Pharmaceuticals Holding AB; Infinity Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; Janssen Biotech, Inc.; Johnson & Johnson; Kissei Pharmaceutical Co., Ltd.; LG Sciences; Lupin Ltd.; Mochida Pharmaceutical Co., Ltd.; Mylan Pharmaceutical Pvt. Ltd.; Neovacs SA; Nogra Pharma Limited; NovaMedica LLC; Novartis International AG; Osiris Therapeutics, Inc.; Otsuka Pharmaceutical Co., Ltd.; PAR Pharmaceutical Companies, Inc.; PendoPharm, Inc.; Perrigo Company PLC; Pfenex, Inc.; Pfizer, Inc.; Pharmascience Inc.; Pluristem Therapeutics, Inc.; Qu Biologics Inc.; Quest Diagnostics, Inc.; RedHill Biopharma Ltd.; Reliance Life Sciences; Salix Pharmaceuticals, Inc.; Sandoz International GmbH; Sanofi; Sequella, Inc.; Soligenix, Inc.; Takeda Pharmaceutical Co., Ltd.; Teva Pharmaceutical Industries Ltd.; Toray Industries, Inc.; Torrent Pharmaceuticals Ltd.; UCB SA; Zeria Pharmaceutical Co., Ltd.

SEGMENTS

» Drug Class (TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors, Other Drug Classes) » Type (Crohn`s Disease, Ulcerative Colitis) » Route of Administration (Injectable, Oral) » Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Inflammatory Bowel Disease (IBD) Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for 69 Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for TNF inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for TNF inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for TNF inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Anti-integrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Anti-integrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Anti-integrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Aminosalicylates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Aminosalicylates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Aminosalicylates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for IL inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for IL inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for IL inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for JAK inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for JAK inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for JAK inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Crohn`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Crohn`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Crohn`s Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
World Inflammatory Bowel Disease (IBD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
UNITED STATES
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
JAPAN
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
CHINA
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
EUROPE
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
FRANCE
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
GERMANY
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
UNITED KINGDOM
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
SPAIN
Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Spain Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
RUSSIA
Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Russia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
AUSTRALIA
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Australia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
INDIA
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
India Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
SOUTH KOREA
South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
South Korea Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
LATIN AMERICA
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
ARGENTINA
Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Argentina Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
BRAZIL
Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Brazil Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
MEXICO
Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Mexico Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
REST OF LATIN AMERICA
Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Rest of Latin America Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
MIDDLE EAST
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
IRAN
Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Iran Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
ISRAEL
Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Israel Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
SAUDI ARABIA
Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Saudi Arabia Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
UNITED ARAB EMIRATES
UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
UAE Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
REST OF MIDDLE EAST
Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Rest of Middle East Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
AFRICA
Inflammatory Bowel Disease (IBD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Drug Class - Percentage Breakdown of Value Sales for TNF inhibitors, Anti-integrin, Corticosteroids, Aminosalicylates, IL inhibitors, JAK inhibitors and Other Drug Classes for the Years 2012, 2021 & 2027
Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Crohn`s Disease and Ulcerative Colitis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Type - Percentage Breakdown of Value Sales for Crohn`s Disease and Ulcerative Colitis for the Years 2012, 2021 & 2027
Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Injectable and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Injectable and Oral for the Years 2012, 2021 & 2027
Africa Recent Past, Current & Future Analysis for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Inflammatory Bowel Disease (IBD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027
Total Companies Profiled: 69

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com